Mind Medicine (MMQ) Stock Forecast & Price Target

Compare

11 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

MMQ Analyst Ratings

Strong Buy

8 Buy

0 Hold

0 Sell

Based on 8 analysts giving stock ratings to

Mind

Medicine

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

MMQ Stock 12 Month Forecast

Average Price Target

€24.30

▲(132.56% Upside)

Based on 8 Wall Street analysts offering 12 month price targets for Mind Medicine in the last 3 months. The average price target is €24.30 with a high forecast of €47.31 and a low forecast of €15.48. The average price target represents a 132.56% change from the last price of €10.45.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"€4","15":"€15","26":"€26","37":"€37","48":"€48"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":47.3148401,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">€47.31</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24.302622415,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">€24.30</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":15.48485676,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">€15.48</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,15,26,37,48],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,14.753449238461538,17.466898476923078,20.180347715384613,22.893796953846152,25.60724619230769,28.320695430769227,31.034144669230766,33.747593907692305,36.46104314615384,39.174492384615384,41.88794162307692,44.601390861538455,{"y":47.3148401,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,12.983278647307692,13.926557294615383,14.869835941923077,15.813114589230768,16.75639323653846,17.699671883846154,18.642950531153843,19.586229178461537,20.52950782576923,21.472786473076923,22.416065120384616,23.35934376769231,{"y":24.302622415,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.04,12.304988981538461,12.569977963076923,12.834966944615385,13.099955926153845,13.364944907692307,13.629933889230768,13.89492287076923,14.159911852307692,14.424900833846152,14.689889815384614,14.954878796923076,15.219867778461538,{"y":15.48485676,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":5.72,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.935,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 13, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.505,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.89,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.475,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.38,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.47,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.29,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.6,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.18,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.8,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.09,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.04,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target€47.31

Average Price Target€24.30

Lowest Price Target€15.48

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Patrick Trucchio

H.C. Wainwright

€47.31

Buy

352.77%

Upside

Reiterated

11/11/25

H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)

Michael Okunewitch

Maxim Group

€15.48

Buy

48.18%

Upside

Reiterated

11/10/25

Mind Medicine's Strong Financial Position and Clinical Progress Drive Buy Rating

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

€19.79

Buy

89.34%

Upside

Reiterated

11/10/25

Mind Medicine (MNMD) Receives a Buy from Evercore ISI

Ami Fadia

Needham

€24.09

Buy

130.50%

Upside

Reiterated

11/07/25

Mind Medicine's Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future

Jay Olson

Oppenheimer

€21.51

Buy

105.81%

Upside

Reiterated

11/07/25

Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)

Sumant Kulkarni

Canaccord Genuity

€13.76→€21.51

Buy

105.81%

Upside

Reiterated

11/07/25

Mind Medicine price target raised to $25 from $16 at CanaccordMind Medicine price target raised to $25 from $16 at Canaccord

Francois Brisebois

LifeSci Capital

€27.53

Buy

163.43%

Upside

Reiterated

11/07/25

Mind Medicine's Promising Clinical Progress and Strategic Advancements Justify Buy Rating

Brian Abrahams

RBC Capital

€17.21

Buy

64.64%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Mind Medicine (NASDAQ: MNMD) and Tandem Diabetes Care (NASDAQ: TNDM)

Jason Wittes

Roth MKM

€30.97

Buy

196.36%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Rudy Li

Chardan Capital

€17.21

Buy

64.64%

Upside

Reiterated

08/01/25

Mind Medicine (MNMD) Receives a Buy from Chardan Capital

Marc Goodman

Leerink Partners

€17.21

Buy

64.64%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Joel Beatty

Robert W. Baird

€23.23→€13.76

Buy

31.72%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Patrick Trucchio

H.C. Wainwright

€47.31

Buy

352.77%

Upside

Reiterated

11/11/25

H.C. Wainwright Sticks to Its Buy Rating for Mind Medicine (MNMD)

Michael Okunewitch

Maxim Group

€15.48

Buy

48.18%

Upside

Reiterated

11/10/25

Mind Medicine's Strong Financial Position and Clinical Progress Drive Buy Rating

Unknown Analyst

Evercore ISI

Not Ranked

Evercore ISI

€19.79

Buy

89.34%

Upside

Reiterated

11/10/25

Mind Medicine (MNMD) Receives a Buy from Evercore ISI

Ami Fadia

Needham

€24.09

Buy

130.50%

Upside

Reiterated

11/07/25

Mind Medicine's Accelerated Phase 3 Trials and Strong Financial Position Signal Promising Future

Jay Olson

Oppenheimer

€21.51

Buy

105.81%

Upside

Reiterated

11/07/25

Oppenheimer Sticks to Its Buy Rating for Mind Medicine (MNMD)

Sumant Kulkarni

Canaccord Genuity

€13.76→€21.51

Buy

105.81%

Upside

Reiterated

11/07/25

Mind Medicine price target raised to $25 from $16 at CanaccordMind Medicine price target raised to $25 from $16 at Canaccord

Francois Brisebois

LifeSci Capital

€27.53

Buy

163.43%

Upside

Reiterated

11/07/25

Mind Medicine's Promising Clinical Progress and Strategic Advancements Justify Buy Rating

Brian Abrahams

RBC Capital

€17.21

Buy

64.64%

Upside

Reiterated

11/06/25

Analysts Offer Insights on Healthcare Companies: RegenXBio (NASDAQ: RGNX), Mind Medicine (NASDAQ: MNMD) and Tandem Diabetes Care (NASDAQ: TNDM)

Jason Wittes

Roth MKM

€30.97

Buy

196.36%

Upside

Reiterated

08/04/25

Analysts Are Bullish on Top Healthcare Stocks: Mind Medicine (MNMD), Axsome Therapeutics (AXSM)

Rudy Li

Chardan Capital

€17.21

Buy

64.64%

Upside

Reiterated

08/01/25

Mind Medicine (MNMD) Receives a Buy from Chardan Capital

Marc Goodman

Leerink Partners

€17.21

Buy

64.64%

Upside

Reiterated

08/01/25

Mind Medicine's Promising Pipeline and Financial Stability Drive Buy Rating

Unknown Analyst

Cantor Fitzgerald

Not Ranked

Cantor Fitzgerald

―

Buy

―

Reiterated

05/29/25

Mind Medicine (MNMD) Receives a Buy from Cantor Fitzgerald

Joel Beatty

Robert W. Baird

€23.23→€13.76

Buy

31.72%

Upside

Reiterated

03/07/25

Mind Medicine price target lowered to $16 from $27 at BairdMind Medicine price target lowered to $16 from $27 at Baird

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Mind Medicine

1 Month

xxx

Success Rate

5/9 ratings generated profit

Average Return

+7.81%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 55.56% of your transactions generating a profit, with an average return of +7.81% per trade.

3 Months

xxx

Success Rate

7/9 ratings generated profit

Average Return

+22.29%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 77.78% of your transactions generating a profit, with an average return of +22.29% per trade.

1 Year

Patrick TrucchioH.C. Wainwright

Success Rate

18/20 ratings generated profit

Average Return

+77.46%

reiterated a buy rating last month

Copying Patrick Trucchio's trades and holding each position for 1 Year would result in 90.00% of your transactions generating a profit, with an average return of +77.46% per trade.

2 Years

xxx

Success Rate

13/13 ratings generated profit

Average Return

+142.42%

reiterated a xxx

rating last month

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +142.42% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

MMQ Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, MMQ has received 14 Buy Ratings, 0 Hold Ratings, and 0 Sell Ratings. MMQ average Analyst price target in the past 3 months is 24.30.

Each month's total comprises the sum of three months' worth of ratings.

MMQ Financial Forecast

MMQ Earnings Forecast

Next quarter’s earnings estimate for MMQ is -€0.44 with a range of -€0.63 to -€0.32. The previous quarter’s EPS was -€0.66. MMQ beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.07% of the time in the same period. In the last calendar year MMQ has Performed in-line its overall industry.

No data currently available

MMQ Sales Forecast

Next quarter’s sales forecast for MMQ is €0.00 with a range of €0.00 to €0.00. The previous quarter’s sales results were €0.00. MMQ beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.62% of the time in the same period. In the last calendar year MMQ has Performed in-line its overall industry.

MMQ Stock Forecast FAQ

What is DE:MMQ’s average 12-month price target, according to analysts?

Based on analyst ratings, Mind Medicine’s 12-month average price target is 24.30.

What is DE:MMQ’s upside potential, based on the analysts’ average price target?

Mind Medicine has 132.56% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Mind Medicine a Buy, Sell or Hold?

Mind Medicine has a consensus rating of Strong Buy, which is based on 8 buy ratings, 0 hold ratings and 0 sell ratings.

What is Mind Medicine’s share price target?

The average share price target for Mind Medicine is 24.30. This is based on 8 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is €47.31 ,and the lowest forecast is €15.48. The average share price target represents 132.56% Increase from the current price of €10.45.

What do analysts say about Mind Medicine?

Mind Medicine’s analyst rating consensus is a Strong Buy. This is based on the ratings of 8 Wall Streets Analysts.

How can I buy shares of Mind Medicine?

To buy shares of DE:MMQ, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Mind Medicine (MMQ) Stock Forecast & Price Target

MMQ Analyst Ratings

MMQ Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Mind Medicine

MMQ Analyst Recommendation Trends

MMQ Financial Forecast

MMQ Earnings Forecast

MMQ Sales Forecast

MMQ Stock Forecast FAQ

Detailed List of Analyst Forecasts